DSM Pharmaceutical Products and Agennix AG have signed a new contract under which DSM will continue to provide commercial manufacture of talactoferrin for Agennix. DSM is currently manufacturing talactoferrin for ongoing clinical trials and will continue to supply clinical trials as well as a potential commercial launch.

Under the contract, DSM will manufacture the oral Dendritic Cell Mediated Immunotherapy (DCMI) talactoferrin at commercial levels in anticipation of positive Phase III results and product approval. The contract includes the opportunity to expand production capacity as needed. Financial terms were not disclosed.

Rajesh Malik, M.D., chief medical officer and management board member of Agennix, said, “We are pleased to continue our productive relationship with DSM. Their long-term experience with talactoferrin will be invaluable as we work with them in preparation for a potential product approval and subsequent commercialization of talactoferrin. It is important for Agennix to put in place now the key elements of the talactoferrin supply chain, and expanding our contract with DSM is an important part of this process.”

Villaume Kal, vice president of DSM BioSolutions, a business unit of DSM Pharmaceutical Products, said, “This agreement recognizes intensive collaboration between DSM and Agennix. DSM’s process design for application in large scale manufacturing largely contributed to this success and we are delighted to continue our support of Agennix.”